Covidh Technologies Limited has signed a non-binding Letter of Intent with iSERA Biological Limited to acquire its entire equity stake. The proposed acquisition, subject to due diligence and regulatory approvals, would make iSERA a wholly owned subsidiary of Covidh Technologies.
Covidh Technologies Limited announced on February 23, 2026, that it has entered into a non-binding Letter of Intent with iSERA Biological Limited for the acquisition of 100% equity shareholding. This strategic move highlights Covidh’s intent to strengthen its position in the biotechnology sector and expand its portfolio.
Key Highlights
-
The Letter of Intent sets out broad terms and conditions for the proposed acquisition
-
Completion of the transaction depends on definitive agreements, due diligence, and regulatory approvals
-
Once finalized, iSERA Biological Limited will become a wholly owned subsidiary of Covidh Technologies
-
Binding provisions in the LOI cover confidentiality, exclusivity, governing law, and costs
-
Further disclosures will follow in line with SEBI regulations upon execution of definitive agreements
This development marks a significant step in Covidh Technologies’ growth strategy, positioning the company to enhance its presence in the life sciences domain and leverage synergies with iSERA Biological Limited.
Source: Covidh Technologies Limited, BSE Filing dated February 23, 2026.